Posts Archive

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in RRMM

NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma

NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM

NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma

NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)

NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for ASCT

NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma

NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4

NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)

NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM

NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory MM

NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM

NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines

NCT03940833: Phase 1/2: Adoptive BCMA CAR-NK Cells - RRMM

NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM

NCT03859427: Phase 3: Once-weekly vs Twice-wkly Carfilzomib + Lenalidomide + Dex RRMM - A.R.R.O.W.2

NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With RRMM (LUMMICAR STUDY 1)

NCT03836053: Phase 1b - AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma AMG420